These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 3409457)

  • 1. The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfonylamino)phenylamino]-4 -acridinecarboxamide (CI-921) in a phase 1 trial.
    Paxton JW; Hardy JR; Evans PC; Harvey VJ; Baguley BC
    Cancer Chemother Pharmacol; 1988; 22(3):235-40. PubMed ID: 3409457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of cimetidine, phenobarbitone and buthionine sulphoximine on the disposition of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulphonylamino)phenylamino]- 4-acridinecarboxamide (CI-921) in the rabbit.
    Paxton JW; Evans PC; Hardy JR
    Cancer Chemother Pharmacol; 1989; 23(5):291-5. PubMed ID: 2706733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice.
    Kestell P; Paxton JW; Evans PC; Young D; Jurlina JL; Robertson IG; Baguley BC
    Cancer Res; 1990 Feb; 50(3):503-8. PubMed ID: 2297692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of the amsacrine analogue 9-[( 2-methoxy-4-[(methylsulfonyl)amino]-phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921).
    Hardy JR; Harvey VJ; Paxton JW; Evans P; Smith S; Grove W; Grillo-Lopez AJ; Baguley BC
    Cancer Res; 1988 Nov; 48(22):6593-6. PubMed ID: 3180070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-dependent pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]- 4-acridinecarboxamide (CI-921) in rabbits.
    Paxton JW; Evans PC; Singh RM
    Cancer Chemother Pharmacol; 1987; 20(1):13-5. PubMed ID: 3621447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans.
    Paxton JW; Kim SN; Whitfield LR
    Cancer Res; 1990 May; 50(9):2692-7. PubMed ID: 2328494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH.
    Mross K; Hüttmann A; Herbst K; Hanauske AR; Schilling T; Manegold C; Burk K; Hossfeld DK
    Cancer Chemother Pharmacol; 1996; 38(3):217-24. PubMed ID: 8646795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing.
    Mross K; Holländer N; Frost A; Unger C; Ziroli V; Massing U
    Onkologie; 2006 Oct; 29(10):444-50. PubMed ID: 17028453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The disposition of carboplatin in ovarian cancer patients.
    Gaver RC; Colombo N; Green MD; George AM; Deeb G; Morris AD; Canetta RM; Speyer JL; Farmen RH; Muggia FM
    Cancer Chemother Pharmacol; 1988; 22(3):263-70. PubMed ID: 3044634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
    Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
    Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and toxicity of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after i.v. administration in the mouse.
    Paxton JW; Young D; Evans SM; Kestell P; Robertson IG; Cornford EM
    Cancer Chemother Pharmacol; 1992; 29(5):379-84. PubMed ID: 1551177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia.
    Jurlina JL; Varcoe AR; Paxton JW
    Cancer Chemother Pharmacol; 1985; 14(1):21-5. PubMed ID: 3855288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of food on the bioavailability and kinetics of the anticancer drug amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]-4 acridinecarboxamide in rabbits.
    Paxton JW
    J Pharm Pharmacol; 1986 Nov; 38(11):837-40. PubMed ID: 2879015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the pharmacokinetics and protein binding of the anticancer drug, amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenyl-amino] -4-acridinecarboxamide in rabbits.
    Paxton JW; Jurlina JL
    Cancer Chemother Pharmacol; 1986; 16(3):253-6. PubMed ID: 3754493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, antitumor activity, and DNA binding properties of a new derivative of amsacrine, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino) phenylamino]-4-acridinecarboxamide.
    Baguley BC; Denny WA; Atwell GJ; Finlay GJ; Rewcastle GW; Twigden SJ; Wilson WR
    Cancer Res; 1984 Aug; 44(8):3245-51. PubMed ID: 6547635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer.
    Toussaint C; Izzo J; Spielmann M; Merle S; May-Levin F; Armand JP; Lacombe D; Tursz T; Sunderland M; Chabot GG
    J Clin Oncol; 1994 Oct; 12(10):2102-12. PubMed ID: 7931480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
    Tranchand B; Catimel G; Lucas C; Sarkany M; Bastian G; Evene E; Guastalla JP; Négrier S; Rebattu P; Dumortier A; Foy M; Grossin F; Mazier B; Froudarakis M; Barbet N; Clavel M; Ardiet C
    Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486A in phase I studies in patients with advanced cancers.
    Zhou H; Choi L; Lau H; Bruntsch U; Vries EE; Eckhardt G; Oosterom AT; Verweij J; Schran H; Barbet N; Linnartz R; Capdeville R
    J Clin Pharmacol; 2000 Mar; 40(3):275-83. PubMed ID: 10709156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma pharmacokinetics of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in a phase I trial.
    Kestell P; Dunlop IC; McCrystal MR; Evans BD; Paxton JW; Gamage RS; Baguley BC
    Cancer Chemother Pharmacol; 1999; 44(1):45-50. PubMed ID: 10367748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.